Clinical Trial Update: Safety and Efficacy Study of QL0911 to Treat Immune Thrombocytopenia (ITP) in Pediatric Patients [Phase 3]

View source ↗

Summary

This update announces a Phase 3 safety and efficacy trial of QL0911 for pediatric immune thrombocytopenia that is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• QL0911

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Thrombocytopenia, Immune | Phase 3 | Status: NOT_YET_RECRUITING